Asia-Pacific silent heart attack market is estimated to grow at a CAGR of around 7.5% during the forecast period. High population base, increasing cases of heart attack, and rising awareness for cardiovascular diseases (CVDs) and other heart conditions among people are some of the major factors that are boosting the market growth in the region. Additionally, the rising healthcare expenditure and a significant rise in the standards of living are the key factors that are propelling the growth of the silent heart attack diagnosis and treatment market in the region. The developing economies of Asia-Pacific, especially China, Japan, and India are investing significantly in the development of innovative therapeutic and medical devices. Furthermore, the presence of various subsidiaries of major market players in Asia-Pacific is again estimated to boost the market growth. For instance, major companies in the market such as AstraZeneca PLC, Bayer AG, Bristol-Myers Squibb Co., have their subsidiary companies in all the major economies in the region.
To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/asia-pacific-silent-heart-attack-market
Asia-Pacific silent heart attack market is segmented into diagnosis, treatment, and end-user. Based on the diagnosis, the market is segmented into an electrocardiography (ECG), chest x-ray, computed tomography (CT Scan), echocardiography, and others (blood test). Based on treatment, the market is segmented into medication and surgery. Based on end-user, the market is segmented into hospitals & clinics and ambulatory surgical centers (ASCs). Hospitals and clinics are the major end-users of devices, medications, and diagnostic tools used for the silent heart attack diagnosis and treatment. Every patient who is suffering from a silent heart attack looks for a hospital or clinic for the treatment, which boosts the demand for devices and medicines in the segment.
The companies which are contributing to the growth of the Asia-Pacific silent heart attack market include AstraZeneca PLC, Hoffmann-La Roche Ltd., Boehringer Ingelheim GmbH, Terumo Corp., and Siemens AG. The market players are considerably contributing to the market growth by the adoption of various strategies including new product launch, merger, and acquisition, collaborations with government, funding to the start-ups, and technological advancements to stay competitive in the market.
Asia-Pacific Silent Heart Attack Market- Segmentation
By Diagnosis
- Electrocardiography (ECG)
- Magnetic Resonance Imaging (MRI)
- Computed Tomography (CT Scan)
- Echocardiography
- Others (Blood Test)
By Treatment
- Medication
- Surgery
- By End-User
- Hospital & Clinics
- Ambulatory Surgical Centers
A full report of Asia-Pacific Silent Heart Attack Market is available at: https://www.omrglobal.com/industry-reports/asia-pacific-silent-heart-attack-market
Asia-Pacific Silent Heart Attack Market– Segment by Country
- China
- Japan
- India
- Rest of Asia-Pacific
